

# Price and welfare effects of a pharmaceutical substitution reform

David Granlund\*

The Swedish Retail Institute (HUI)  
SE-103 29 Stockholm, Sweden; and  
Department of Economics, Umeå University  
SE-901 87 Umeå, Sweden  
E-mail: david.granlund@econ.umu.se

June 2009

## Abstract

The price effects of the Swedish pharmaceutical substitution reform are analyzed using data for a panel of all pharmaceutical product sold in Sweden in 1997–2007. The price reduction due to the reform was estimated to average 10% and was found to be significantly larger for brand name pharmaceuticals than for generics. The results also imply that the reform amplified the effect of generic entry has on brand-name prices by a factor of ten. Results of a demand-estimation imply that the price reductions increased total pharmaceutical consumption by 8% and consumer welfare by SEK 2.7 billion annually.

**Keywords:** drugs; generic competition; equivalent variation; demand estimation

**JEL classification:** D40; I11; L65

---

\*I am grateful to Kenneth Carling, Reza Mortazavi, Niklas Rudholm, and participants in a seminar at Dalarna University and participants at the Swedish Workshop on Competition Research in 2009 for their helpful comments and suggestions, and to the Swedish Competition Authority for a research grant that supported the work. I wrote most of this paper while I was a guest researcher at Dalarna University and wish to thank them for their hospitality. I also wish to thank IMS Sweden, the National Corporation of Swedish Pharmacies, the Riksbank and Statistics Sweden for providing the datasets.

## 1 Introduction

In October 2002, the Swedish pharmaceutical market was reformed. The reform requires pharmacists to substitute the cheapest available generic (or parallel-imported product) for the prescribed pharmaceutical product in cases when neither the physician nor the consumer opposes substitution. The reform was supposed to lower pharmaceutical costs directly, as prescribed pharmaceuticals were replaced with cheaper versions, and indirectly through increased price competition. To contain rising pharmaceutical costs, similar reforms have been introduced in many European countries and American states.

The main purpose of this paper is to estimate how the Swedish substitution reform has affected pharmaceutical prices, through its effect on price competition. Based on this, one can calculate how much more current pharmaceutical consumption would have cost without the reform. Since current pharmaceutical consumption levels would not be the same without the price effects of the reform, this is not a very exact measure of the importance of the reform. I therefore quantify the importance of the reform's price effects in terms of equivalent variation, and to this end, I estimate a demand function for pharmaceuticals.

The reform's price effects are estimated using monthly data, from January 1997 through October 2007, on all pharmaceutical products sold in Sweden. Separate estimates are derived for generics, brand-name products that faced generic competition at the time of reform, brand-name products that did not face generic competition at that time, and a group of products belonging to none of these groups (*Others*). The demand for pharmaceuticals is estimated using aggregated quarterly data on pharmaceutical sales from 1980 through 2007.

The results indicate that, in its first five years, the reform lowered average prices of generic pharmaceuticals by 9%, of brand-name pharmaceuticals facing generic competition by 14%, of brand-name pharmaceuticals not facing generic competition by 10%, and of other pharmaceutical products by 5%. The results also indicate that the reform increased the effect of generic competition on brand-name prices. The weighted average price reduction of all pharmaceuticals is estimated to be 10%, which in turn is estimated to have increased total pharmaceutical consumption by 8%. The consumer welfare gains accruing from these price cuts is estimated to average SEK 2.7 billion per year (approximately EUR 290 million)<sup>1</sup>, which can be compared with total Swedish pharmaceutical

---

<sup>1</sup>All monetary values in this paper (except those regarding copayments cited in section 2)

sales of SEK 26.4 billion in 2006. The present value in 2002 of the welfare effects for October 2002 through October 2007 amounts to SEK 12.4 billion.

This paper relates to the limited literature assessing the price effects of substitution reforms and presents the first test of whether or not a substitution reform also affects pharmaceuticals that do not face generic competition. Granlund and Rudholm (2007) estimated that the Swedish substitution reform, in its first four years, reduced the unweighted average prices by 4% for both generics and brand-name pharmaceuticals facing generic competition. These results were obtained by using a specification that allowed prices to gradually adjust to the reform. They obtained significantly smaller effects when they estimated a specification without an adjustment process and concluded that it was important to account for the adjustment. The results of Granlund and Rudholm, though, cannot be used to estimate savings and welfare effects caused by increased price competition, since the reform effect is likely correlated with product sales values, for which they did not account. Using pharmaceutical price index data from 16 OECD countries, Buzzelli et al. (2006) estimated that substitution reforms lowered pharmaceutical prices by 3%. They did, however, not investigate whether or not prices were gradually adjusted to the reforms.<sup>2</sup>

This paper also contributes to the literature analyzing the effect of generic entry on brand-name pharmaceutical prices, by studying how the substitution reform influenced this effect. The empirical results in this literature are mixed. On one hand, Caves et al. (1991) found that the initial entry of generic products led to a reduction in brand-name prices. Similarly, Wiggins and Maness (1994) and Lu and Comanor (1998) found that the number of generic products had a negative effect on brand-name prices. On the other hand, Grabowski and Vernon (1992) and Frank and Salkever (1997) reported that brand-name prices rose in response to generic entry. One explanation of this is that generic entry reduces the own-price elasticity of brand-name products (Frank and Salkever, 1992, 1997). Frank and Salkever (1992) also demonstrated that, if consumers become more price-sensitive, under reasonable conditions this will increase the

---

are deflated by the CPI and expressed in 2007 prices. The average exchange rates in 2007 were USD/SEK = 6.76 and EUR/SEK = 9.25 (the Riksbank).

<sup>2</sup>The National Corporation of Swedish Pharmacies et al. (2003, 2004) aimed to assess the savings due to increased price competition, but did not account for expiring patents or price-trends in their reports and based their estimates on a non-representative sample consisting of the substances with the largest sales values.

downward pressure exerted by generic entry on brand-name prices.

Other related papers estimate price and income elasticities for pharmaceuticals. A few, such as Alexander et al. (1994), examine how the demand for all pharmaceuticals (and not just a single product or group of products) is affected by changed income and pharmaceutical prices (and not just out-of-pocket costs) on a national level. As discussed by Getzen (2000), elasticities vary with the level of analysis, since elasticities on different levels are affected by partly different decisions. The results of the present paper are therefore not directly comparable to those conducted on a micro level. Finally, the present paper relates to studies evaluating welfare effects of different reforms, for example Watal (2000) and Chaudhuri et al. (2006), which both estimated the welfare losses accruing from enforcing pharmaceutical patents in India.

The next section describes the context and the substitution reform. In section three, I discuss the empirical approach, first, for estimating the reform's effects on prices, and second, regarding the welfare measure and the demand function. Section three also contains some descriptive statistics. In section four, I present the results of the various estimations and in section five I discuss other possible welfare effects. Finally, the paper's conclusions are presented in section six.

## 2 Swedish pharmaceutical insurance

Subsidies have covered a large part of the pharmaceutical costs for Swedish consumers ever since pharmaceutical insurance was introduced in 1955. Through the insurance, pharmaceuticals for treating selected diseases were free, while for other pharmaceuticals consumers only paid a limited copayment. In 1980, the copayment was in the form of a maximum dispensing fee of SEK 25 per dispensing occasion. Apart from the changes in the insurance described below, copayment levels have been changed (usually increased) on several occasions since then.<sup>3</sup>

In July 1981, a combined cost limit was introduced for pharmaceuticals, physician consultations and medical treatments, according to which patients

---

<sup>3</sup>The sources used in this section are SFS (1981:49) and the government bills dealing with changes in this law. These bills are listed at [www.notisum.se/rnp/sls/fakta/a9810049.htm](http://www.notisum.se/rnp/sls/fakta/a9810049.htm), 30 October 2008.

mailed zero copayments after a total of 15 pharmaceutical purchases or physician consultations over a 12-month period. In connection with a deregulation of fees for physician consultations in July 1991, this limit was replaced with a maximum annual copayment for pharmaceuticals and healthcare of SEK 1500.

A reference price system was introduced in January 1993. Reference prices were set to 110% of the cheapest available generic products, and costs exceeding these reference prices were not included in the maximum annual copayment limit (RFFS 1992:20, 1996:31).

In January 1997, the reimbursement schemes for healthcare and pharmaceuticals were separated. Copayments were introduced for previously free pharmaceuticals (except insulin) and a stepwise copayment structure was launched for pharmaceuticals. Consumers paid all costs up to SEK 400 per 12-month period, 50% of the cost from SEK 400 to 1200, 25% from SEK 1200 to 2800, and 10% from SEK 2800 to 3800; after this level, all costs in the period were paid by the insurance. As of 1 June 1999, all these break-points were increased by SEK 500, but have since remained unchanged.

## 2.1 The substitution reform

The substitution reform came into effect 1 October 2002 and replaced the reference price system. This reform requires pharmacists to inform consumers whether substitute products are available, and that the cheapest available substitute product would be provided within the Swedish pharmaceuticals insurance system.<sup>4</sup> The pharmacist must also inform consumers that they can buy the prescribed pharmaceutical product instead of the cheapest substitute if they pay the price difference themselves. Finally, the reform requires that pharmacists substitute the cheapest available generic (or parallel-imported product) for the prescribed pharmaceutical product in cases when neither the prescribing physician prohibits the substitution for medical reasons, nor the consumer chooses to pay the price difference between the prescribed and the generic alternative. In cases where the physician prohibits the substitution for medical reasons, the consumer is still reimbursed.

Three characteristics of the substitution reform may have contributed to

---

<sup>4</sup>The Swedish Medical Products Agency defines a product as a substitute if it has the same active substance, strength, and form (e.g. pills or oral fluid) as the prescribed product, and if its package sizes can approximately sum up to the prescribed quantity.

making consumers more price sensitive, which in turn has resulted in more generic substitution and lower pharmaceutical prices. First, the reform lowered the transaction cost of generic substitution, since before the reform it was recommended that the physicians be contacted before substituting products if they had not explicitly consented to substitution on the prescriptions. Second, when substitution is presented as an option (as it always should be after the reform) consumers gain information about that cheaper substitutes exist and can easily gain information also about price differences between the pharmaceutical substitutes. Finally, under the substitution reform, costs up to 100% of the cheapest substitute product are included in the pharmaceutical insurance system, compared with 110% in the reference price system. This increased the consumer's out-of-pocket costs for choosing to buy the prescribed pharmaceutical by 0-10 percent of the price of the cheapest generic version, depending on the patient's copayment rate.

According to a theoretical model presented by Granlund and Rudholm (2007), the substitution reform likely has a greater effect on prices for brands that face generic competition than for generics. The intuition is that, while the reform by making consumers more cross-price sensitive works for lower prices in both product groups, the reform also increases the demand for generics at the expense of the demand for brand-name products, which likely reduces the incentives for generics to lower their prices but increases the likelihood of price cuts for brand-names.

Brand-name products without generic competition are likely affected less by the reform than other brands, but should still be affected. At least some of these products are substitutes for pharmaceuticals subject to generic competition and hence face lower demand as the prices of these pharmaceuticals drop, which – depending on the shape of their demand functions – might cause price cuts. Patent-protected pharmaceuticals might also be directly affected by the substitution reform, since many of them face competition from cheaper parallel-imported pharmaceuticals.

The prices in the *Others* group, consisting, for example, of vitamins and/or minerals, is expected to be affected relatively little by the reform, since few of these products have what the Swedish Medical Products Agency considers to be close substitutes.

## 2.2 Price setting and distribution

Throughout the study period, for a pharmaceutical to be included in the insurance, its price had to be authorized, before October 2002 by the National Social Insurance Board and thereafter by the Pharmaceutical Benefits Board. It was easier for pharmaceutical firms to get Pharmaceutical Benefits Board approvals of price reductions than price increases, except if the new price did not exceed the price of the most expensive exchangeable product.<sup>5</sup> This fact, together with pharmaceutical firms' incomplete information about the reactions of physicians, consumers and other pharmaceutical firms to the reform, gave firms an incentive to adjust their prices gradually after the reform. Since the exception means that most generics could increase their prices as easy as they could reduce them, we might expect fastest price adjustments for generics; but, since their brand-competitors likely will not adjust their price immediately, neither will the generics.

Throughout the study period, pharmaceuticals were sold through a nationwide government owned monopoly, the National Corporation of Swedish Pharmacies, which paid and charged uniform prices nationwide for each pharmaceutical product.

## 3 Empirical specifications and data

### 3.1 Estimating the reform's effects on prices

The reform's effect on prices is estimated separately for *Generics*,<sup>6</sup> brand-name pharmaceuticals that faced generic competition at the time of reform (*BrandC*), brand-name pharmaceuticals that did not face generic competition at that time (*BrandM*), and a group of products belonging to none of these

---

<sup>5</sup>The Pharmaceutical Benefits Board is required to decide whether to approve price cuts as soon as possible, but is allowed 90 days (or under some circumstances 150 days) to handle applications for price increase (SFS 2002:687). Firms must justify price increases, but not price reductions. Also, the Pharmaceutical Benefits Board is restrictive in allowing price increases and only allows an increase if special reasons exist (LFNFS 2003:1).

<sup>6</sup>The generics group also includes so-called branded generics. Branded generics are generic versions of the pharmaceutical product which are sold under their own product name, while other generics are sold under the substance name, usually followed by the company name.

groups (*Others*).<sup>7</sup>

The specification used for estimating the reform effects is written

$$\ln Price_{it} = \beta_1 D_t + \beta_2 [D_t / (t - R)^\mu] + \beta_3 GC_{it} + \beta_4 Trend_t + \theta_i + \varepsilon_{it}. \quad (R1)$$

The dependent variable is the natural logarithm of the price per package paid by the National Corporation of Swedish Pharmacies, and thus charged by the pharmaceutical companies, for product  $i$  in month  $t$ . Using the pharmacies' purchase prices instead of their selling prices is preferred, since it is the price competition between pharmaceutical firms that is most directly affected by the substitution reform. In the study period, there have been many heterogeneous changes in pharmacies' margins and in their selling prices that are hard to capture in an econometric model. Therefore, using purchase prices instead of selling prices reduces the variance of the estimates.

$D$  is an indicator variable taking the value of one after the substitution reform.  $D/(t - R)$ , where  $t - R$  is the number of months from the reform time, is included to capture the adjustment process. Here, the parameter  $\mu$  measures the curvature of the adjustment process.

$GC_{it}$  is a dummy that takes the value of one from the first month product  $i$  faces generic competition and is only included for the two brand-name populations. Controlling for generic competition is important since, near the time of the substitution reform, the patents expired on the three substances with the highest sales values, which was directly followed by generic entry.<sup>8</sup> In public discussions of the substitution reform in Sweden, the price reductions of these substances have often been used to demonstrate the success of the reform, but the effects of expiring patents and those of the substitution reform have not

---

<sup>7</sup>A product is defined as facing generic competition if at least one generic or branded generic has the same active substance, strength, and form (e.g. pills or oral fluid) as the product. Since, for example, a product comprising 20 pills can be replaced by two packages of 10 pills each, a brand-name product is defined as facing generic competition even if its package size differs from that of its generic competitors.

<sup>8</sup>The substances are Citalopram, Omerazol and Simvastatin, whose combined sales accounted for 7.8% of total pharmaceutical sales in 2002.

That generic competition directly followed expiring patent on these and other products suggests that much of the variation in  $GC_{it}$  is exogenous in the sense that it is explained by expiring patents rather than price changes of the brand-name products. In the absence of strong, truly exogenous instruments, it is preferable to treat this variable as exogenous rather than employing an instrumental variable method.



been disentangled. The estimation approach used here makes it possible to do this and, by comparing the  $GC_{it}$  coefficient between the two brand populations, we can examine how the reform has affected the price effect of generic competition. The ability to control for generic competition is also a major advantage of using data on individual pharmaceutical products instead of just estimating the effect of the reform on a pharmaceutical price index.

A trend variable (*Trend*) is included to account for possible common price trends. Finally, product-specific fixed effects ( $\theta_i$ ) are included. These capture all the time-invariant differences in price levels between pharmaceutical products and thus make it possible to use price per package in the dependent variable. This is an important advantage, since the alternate quantity measure, number of defined daily doses, is undefined for 13% of the observations.

By letting the prices adjust gradually to the substitution reform, the estimation approach used here follows Granlund and Rudholm (2007). The specification assumes that the potential price adjustment was largest directly after the reform and gradually decreased as time passed. This is a logical assumption, since pharmaceutical firms do not instantaneously adjust their prices to a new long-term price level because of their limited knowledge of how physicians, consumers and other pharmaceutical firms will react to the reform, and since this knowledge likely increased fastest directly after the reform when the knowledge level was lowest. However, it is difficult to make any a priori assumptions about the speed of this process, so  $\mu$  is allowed to be determined by the data.

This specification of the adjustment is likely to give good estimates of the reform effects in the study period. It is, however, unsuitable for out-of-sample predictions (at least, for predictions into the far future), since the specification assumes that – unless the adjustment is instantaneous (i.e.,  $\beta_2=0$ ) – the adjustment will continue indefinitely. An alternate approach sometimes used in reform evaluations is to let the trend slope change with the reform. This is reasonable when evaluating reforms that might indeed change the trend slope, but when considering a reform like that examined here, which presumably will result in a new long-term price level but not a new long-term price trend, the risk of this approach is that it will ascribe price-changes unrelated to the reform, to the reform effect.<sup>9</sup>

---

<sup>9</sup>These changes could be caused, for example, by the introduction of new pharmaceuticals that lower the demand for pharmaceutical for which they are substitutes and by changes in pharmaceutical markets in other countries (e.g., regarding price-controls).

As mentioned above, the break-points in the pharmaceutical insurance were increased by SEK 500 in June 1999. One might expect that this would have reduced the demand for pharmaceuticals and made consumers more price sensitive by increasing their copayment rates. This, in turn, might have encouraged pharmaceutical firms to lower their prices. However, due to the construction of Swedish pharmaceutical insurance and due to the skewed distribution of consumers' pharmaceutical consumption, most of the pharmaceuticals were bought by consumers who, regardless of this increase, had zero marginal cost for pharmaceuticals.<sup>10</sup> Therefore, this change likely had, at most, minor effects on prices. I have tested to control for the increased break-points, and for delayed responses to this increase and to the insurance changes of January 1997, but since I found no price effects in any sample and since controlling for this did not affect the results for the parameters of interest more than marginally, I am not reporting these results.

Letting the parameter estimates differ between the four pharmaceutical groups will improve the efficiency of the estimates, since these groups are likely to be differently affected by the reform. It is also interesting in itself to obtain separate estimates for each of the four groups, in particular, to test whether the substitution reform also affected the prices of pharmaceuticals for which there are no generic substitutes. I have chosen to split the population, instead of using interaction variables, to keep the models nonlinear in only one variable, the adjustment variable  $D/(t - R)$ . This allows the specification to be easily estimated using a grid-search estimation strategy. This method is employed for each model by setting  $\mu$  to values ranging from 0 to 5 and then estimating the remaining parameters using a Prais-Winsten estimator that corrects for first-order serial correlation in the error terms. Finally, likelihood values were used to discriminate between the different parameter values. The likelihood values were also used to calculate 95% confidence intervals for the adjustment parameter,  $\mu$ . As can be seen in Table 3, the confidence intervals are not symmetrical around the point estimates. This is expected, since a value of  $\mu$  equaling zero leads to an empirical model where the adjustment variable equals the reform

---

<sup>10</sup>Data from the county of Västerbotten show that 54–61% of the pharmaceuticals in 2000 were bought by consumers, who had reached the new highest break-point of the insurance before, or on, the current purchasing occasion. Since at the time of purchasing, consumers are on average approximately 6 months into the 12-month insurance period, a higher share than this had a marginal cost of zero after the reform as well.

indicator variable.

In all estimations, the observations are assigned weights that equal the products' total sales values in the study period; if the reform effects are correlated with sales values, this is necessary when estimating how the reform affected the pharmaceutical price levels. As for price indexes, there are several alternate sets of weights that can be used, so I have reported the results obtained also when using pre-reform sales as weights.

### 3.2 Demand and welfare estimation

Hausman (1981) demonstrated that knowledge of the uncompensated (i.e., the Marshallian) demand function is all that is needed to establish an exact measure of the welfare effects caused by changed prices. The welfare effects can be expressed either in terms of compensating variation (CV) or, as here, in terms of equivalent variation (EV).

In this context, the EV formula derived by Hausman is written

$$EV = - \left\{ \frac{(1 - \gamma_2)}{(1 + \gamma_1) I^{\gamma_2}} [P_{ref} Q(P_{ref}, I) - P_{alt} Q(P_{alt}, I)] + I^{(1 - \gamma_2)} \right\}^{1/(1 - \gamma_2)} + I,$$

where  $\gamma_1$  is the price elasticity of demand and  $\gamma_2$  is the income elasticity of demand, both of which must be estimated.  $P_{ref}$  is the index for pharmacies' selling prices of pharmaceuticals, and  $P_{alt}$  is given by  $P_{alt} = P_{ref}(1 - ARE)$ . *ARE* is short for the average reform effect and is obtained by weighting together the predicted reform effects for the four pharmaceutical groups. The difference between the coefficient of  $GC_{it}$  after and before the reform is treated as part of the reform effects. Finally,  $Q(\cdot)$  is the predicted annual pharmaceutical demand at various price levels and  $I$  is annual income.

If both the price and the income elasticity equal zero, the EV measures equal the extra amount the consumption after the reform would have cost without the price-lowering effect of the reform. Since  $P_{ref}$  is an index for the full prices of pharmaceuticals, and not only the out-of-pocket prices paid by the consumers, the EV will measure the welfare effects of the price cuts for the whole consumer side of the market, both directly for the consumers and for the insurers. The cost of the pharmaceutical insurance is still paid for by the consumers – in the Swedish case, by income taxes – but the distinction is still important if, for example, one wishes to consider the distributional effects of the reform.

Bear in mind that the reform effects are estimated using the pharmacies' purchase prices. Nevertheless, I have still chosen to use the pharmacies' selling prices in the EV measures and in estimating the price elasticity ( $\gamma_1$ ). The justification is that pharmaceutical demand is most closely related to the selling prices. If the pharmacies' margins are affected by the reform, however, the choice may cause an inconsistency in the EV measures. As reported in the Results section, the Pharmaceutical Benefits Board has allowed increased margins because the substitution reform has increased pharmacies' costs. However, it is impossible to know whether some of these increases would have been allowed in any case, even without the reform, and then justified on other grounds. In the Results section, I therefore focus on the EV measures obtained by assuming that margins were unaffected by the reform, but also report EV measures obtained by adjusting the average reform effect (*ARE*) in line with the margin changes justified by the substitution reform.

Since I want to calculate the EV for the substitution reform that has affected the entire pharmaceutical market, and not just the prices of a few drugs, the price and income elasticity should be estimated on an aggregated level.<sup>11</sup> Since the elasticities might differ between countries, the estimation should preferably be done using Swedish data. As mentioned above, no cross-sectional variation in pharmaceutical prices was allowed in Sweden in the study period, implying that the demand function (or at least the price elasticity) must be identified using only variation over time. As discussed below, several difficulties are associated with this, so I will also calculate the EV measures based on demand estimates made for other countries.

Two specifications for the uncompensated pharmaceutical demand in Sweden are estimated. They are both inspired by a specification in Alexander et al. (1994) and are summarized as follows

$$\begin{aligned} \Delta \ln Q_t = & \alpha + \gamma_1 \Delta \ln P_t + \gamma_2 \Delta \ln I_t + \gamma_3 \Delta Trend_t \\ & + \sum_{q=2}^4 \theta_q \Delta Quarter_{qt} + \gamma_4 \Delta Hoard_t + \varepsilon_t, \end{aligned} \quad (D1)$$

---

<sup>11</sup>Deriving the price elasticity of aggregated consumption from demand estimates based on product level data is unfeasible since it would require the estimation of all relevant cross-price elasticities between the nearly 15,000 pharmaceutical products.

$$\begin{aligned} \ln Q_t = & \alpha + \gamma_1 \ln P_t + \gamma_2 \ln I_t + \gamma_3 Trend_t + \sum_{q=2}^4 \theta_q Quarter_{qt} \quad (D2) \\ & + \gamma_4 Hoard_t + \gamma_5 \ln Q_{t-1} + \gamma_6 \ln Q_{t-4} + \varepsilon_t. \end{aligned}$$

$Q_t$  is defined as the pharmacies' total purchase of pharmaceuticals in quarter  $t$ , measured in SEK per 1000 inhabitants and working day, and divided by an index for pharmacies' purchase prices.  $P_t$  is the index for pharmacies' selling prices of pharmaceuticals and  $I$  is GDP per capita in SEK 1000.  $\ln$  indicates that the natural logarithms of the variables are used and  $\Delta$  indicates that the first differences of the variables are used (e.g.,  $\Delta \ln Q_t = \ln Q_t - \ln Q_{t-1}$ ). A trend variable is included and complemented by three quarter-dummies, since Andersson et al. (2007) report that there are seasonal variations in the sales values of pharmaceuticals.<sup>12</sup>

The variable *Hoard* is included to capture the hoarding that is observed in the quarters before increases in the patients' copayment shares and the corresponding decline in sales in the quarters directly after the changes. For a quarter after changed rules that increased patients' copayment shares, *Hoard* equals the percentage increase in the consumer price index for pharmaceuticals compared with the preceding quarter; *Hoard* equals the negative value of that increase for a quarter preceding such a change and 0 otherwise. Hence, the parameter for this variable will estimate the demand shift between subsequent quarters induced by stockpiling. When calculating the consumer price index for pharmaceuticals, Statistics Sweden ignores the fact that the consumers' copayment shares are decreasing functions of pharmaceutical prices. The effects of changed pharmaceutical prices on consumer prices are therefore exaggerated in the consumer price index for pharmaceuticals. This might result in some measurement error of *Hoard* and more severe measurement errors in the index itself, so it is not included in the specifications.

According to Dickey-Fuller tests, it cannot be rejected that the time series  $\ln Q$ ,  $\ln P$  and  $\ln I$  have unit roots. Since this non-stationarity might result in spurious regression it should be addressed. In this paper, two alternate approaches, each with different flaws and merits, are used to address non-stationarity. The first is to make a first-difference transformation (specification

---

<sup>12</sup>Unlike Alexander et al. (1994), I do not take the natural logarithm of the trend variable, since this would mean that the percentage change in the pharmaceutical consumption is assumed to decline with time.

D1) and the second is to include lagged values of pharmaceutical consumption (specification D2). The choice to include the first and fourth lags ( $\ln Q_{t-1}$  and  $\ln Q_{t-4}$ ) is based on the Akaike information criterion (Greene, 2003, Chapter 8).

Both specifications ensure that the error terms are stationary and that the results are therefore not spurious. The first specification addresses the non-stationarity of all variables and is suitable for estimating short-term effects. However, if  $\ln P$  is endogenous, this approach is difficult to use since it is inherently hard to find strong instruments for the first difference of  $\ln P$ . Regarding the second specification, it should be noted that the coefficients for lagged consumption can easily capture the effects of omitted variables and therefore should not be interpreted as estimates of persistency in pharmaceutical consumption. Hence, the long-term effects cannot be estimated using this specification.<sup>13</sup> Due to the auto-regressive processes of  $\ln P$  and  $\ln I$ , there is also a risk that some of the effects of these variables will be attributed to the coefficients for lagged pharmaceutical consumption. A conclusion that can be drawn from this discussion is that the second specification is useful in investigating whether or not  $\ln P$  is endogenous, but if  $\ln P$  is not endogenous, or only weakly so, the first specification is preferable.

Endogeneity has been discussed previously in this context. For example, Reekie (1978) assumed that sellers of pharmaceuticals set prices each period and offer to sell indefinitely large amounts at that price in the period, arguing that prices are therefore determined largely by non-demand-related factors and thus can be treated as exogenous. It should, however, be noted that even if prices are predetermined, as they are on the Swedish market, demand expectations might play a role in the price setting, which might cause some endogeneity problems.

The specifications are estimated using both OLS and IV estimators and the error terms are allowed to be correlated within calendar years. In the IV estimations,  $\ln P$  is instrumented with its second and fourth lag and with the first and second lag of the variable  $\ln TCW$ .  $TCW$  is the total competitiveness weights index, which measures the value of the Swedish crown (SEK) against a basket of other currencies. The lags of  $\ln TCW$  are included as instruments mainly to capture the sharp declines in the value of the Swedish crown that occurred

---

<sup>13</sup>I have tried to estimate long-term elasticities using error-correction models, but failed to obtain reliable estimates, likely because  $\ln Q$ ,  $\ln P$  and  $\ln I$  are not cointegrated; at least a residual-based test provides no support for cointegration.

when it was devaluated in September 1981 (-10%) and October 1982 (-16%) and when Sweden abandoned the fixed exchange rate in November 1992, which resulted in a depreciation of approximately 21% within three months. These events were likely unexpected when pharmaceutical prices were set and therefore likely caused price changes. Several other instruments, and combination of instruments, have also been tested. The choice of instrument-set is based on the Kleibergen-Paap weak identification statistic, which measures the strength of the instruments, and the Hansen J statistic, which tests the validity of the instruments.

### 3.3 Descriptive statistics

The company IMS Sweden provided monthly data on the sales values and quantities of all pharmaceuticals sold in Sweden from January 1997 through October 2007. Table 1 presents descriptive statistics for the variables created from this dataset, which is used when estimating the reform effects on prices.

The means of  $\ln Price$  are not easily comparable between the four groups since they represent the prices of very heterogeneous products. Still, it is not surprising to find the highest average among the brand-name pharmaceuticals that did not face generic competition at the time of reform.

Table 1. Weighted means of variables used in the price estimations

Variable	<i>Generics</i>	<i>BrandC</i>	<i>BrandM</i>	<i>Others</i>
$\ln Price$	4.56	5.22	6.80	5.79
$D$	0.52	0.46	0.53	0.50
$GC$	0.00	0.81	0.04	0.00
$Trend$	69.80	65.01	70.91	68.23
Observations	228 730	83 462	405 086	152 708
Products	4 232	989	6 267	3 216
Market share	0.13	0.09	0.65	0.13

Note: The products' total sales values in the study period are used as weights.

In the *BrandC* population 364 of the 989 products gained generic competition some time after the beginning of the study period, but Table 1 shows that the weighted frequency of observations without competition is only 19%. In the *BrandM* population, 810 of the 6,267 products gained generic competition at some time after the reform, but the weighted frequency of observations facing

competition is only 4%. The market shares show that *BrandM* is by far the most important population in terms of sales values.

The variables used in the demand specifications are based on data provided by the National Corporation of Swedish Pharmacies, the Riksbank, and Statistics Sweden. Descriptive statistics for these variables are given in Table 2. Figure 1 illustrates how the three main variables have changed over time, indicating, for example, that there is seasonal variation in both GDP per capita and the purchase of pharmaceuticals.

Table 2. Means of variables used in the demand estimations

Variable	Level	First-difference
$\ln Q$	3.34	0.02
$\ln P$	5.35	-0.01
$\ln I$	4.12	0.00
<i>Trend</i>	56.5	1.00
<i>Hoard</i>	0.00	0.00
$\ln TCW$	4.71	0.00
Observations	112	111

Note: No data are missing, so 25% of the observations are from each quarter




Figure 1. Depictions of three time series used in the demand estimations



## 4 Results

### 4.1 Estimated reform effects

Table 3 first reports the predicted instantaneous effect of the reform ( $Ref_{inst}$ ), the mean reform effect for October 2002 through October 2007 ( $Ref_{mean}$ ), and the reform effect as of the last month of the study period ( $Ref_{end}$ ). These three all express the percentage effects the reform has had on pharmaceutical prices in each population.  $Ref_{inst}$  equals  $100 * [\exp(\beta_1 + \beta_2) - 1]$  and does not depend on  $\mu$ , since  $t - R$  takes the value of one in the first month of the reform (October 2002), while  $Ref_{mean}$  and  $Ref_{end}$  are calculated also using the estimates of  $\mu$  in accordance with specification (R1).<sup>14</sup> The reform effects at different points in time are also illustrated in Figure 2.

Table 3. Estimation results, percentage effect on prices

	<i>Generics</i>	<i>BrandC</i>	<i>BrandM</i>	<i>Others</i>
$Ref_{inst}(\beta_2, \mu)$	-1.98** (-2.32:-1.65)	-2.45** (-2.72:-2.17)	-0.76** (-0.96:-0.57)	-0.62** (-0.80:-0.43)
$Ref_{mean}(\beta_1, \beta_2, \mu)$	-8.72** (-9.83:-7.62)	-13.97** (-14.86:-13.08)	-10.26** (-10.83:-9.68)	-4.52** (-5.17:-3.86)
$Ref_{end}(\beta_1, \beta_2, \mu)$	-11.22** (-11.99:-9.23)	-17.31** (-18.41:-16.20)	-12.95** (-13.66:-12.23)	-5.68** (-6.50:-4.85)
$GC(\beta_3)$		-0.45* (-0.81:-0.10)	-4.78** (-5.22:-4.35)	
$Trend(\beta_4)$	0.15** (0.13:0.18)	0.33** (0.25:0.42)	0.21** (0.20:0.23)	0.62** (0.59:0.64)
$D/(t - R)(\mu)$	2.9 <sup>-4</sup> ** (0.0<:8.5 <sup>-3</sup> )	2.3 <sup>-4</sup> ** (0.0<:7.0 <sup>-3</sup> )	1.5 <sup>-4</sup> ** (0.0<:1.4 <sup>-3</sup> )	2.3 <sup>-4</sup> ** (0.0<:6.0 <sup>-3</sup> )
Observations	224,498	82,472	398,800	149,490
Products	4,191	988	6,236	3,175
Log likelihood	273,402	155,962	572,372	298,956

Notes: The products' total sales values in the study period are used as weights.

Robust 95% confidence intervals are shown in parentheses.

\*\* and \* denote significance at the 1% and 5% levels, respectively.

<sup>14</sup>Since the reform is a discrete change, the formula  $100 * [\exp(.) - 1]$  must be used to calculate the exact percentage reform effects.

The estimates of  $Ref_{mean}$  indicate that the reform has had significant effects on the prices in all pharmaceutical groups in the study period. The largest relative price cut, 14%, is found in the population of brands that faced generic competition at the time of reform (*BrandC*); the second largest amounts to 10% and is found for brands that lacked generic competition at that time (*BrandM*). A comparison of the estimates for  $GC$  in these two populations reveals another reform effect: the price-effect of getting generic competition goes from being merely -0.45% before the reform to -4.78% after the reform. Together, these results for brand-name pharmaceuticals indicate that the eventual reform effect for those brands that gained generic competition sometime after the reform is similar in size to the effect for those that faced generic competition before the reform.

The lowest estimated average reform effect is -5% for *Others*, while the estimated average reform effect is -9% for *Generics*. The weighted average reform effect over the four pharmaceutical groups is -9.87% (95% C.I. -10.29:-9.45) or -9.66% (95% C.I. -10.07:-9.24) when the effect on  $GC$  is not included.


That prices of generics were reduced less than those of brands that faced generic competition is, as mentioned, in accordance with the theoretical predictions of Granlund and Rudholm (2007). However, Granlund and Rudholm empirically found no significant difference between the two populations. The disparity between their empirical results and those presented here is likely because they did not use weights, which likely have a stronger effect on the estimates for brands, since the sales values for brands are more heterogeneous.

The results also clearly indicate that the pharmaceutical firms had not fully adjusted their prices to the reform already by October 2002: for the different populations, the instantaneous price cuts were 1-2%, compared with declines of 6-17% by the end of the study period. This conclusion is also strengthened by the fact that both  $\beta_2$  and  $\mu$  differ significantly from zero. As expected, the results indicate that the adjustment was fastest for Generics.

The estimates for  $\mu$  assume values below 0.001 in all populations which results in correlations between  $D$  and  $D/(t-R)^\mu$  of above 0.99. Due to these high correlations, the estimates for  $\beta_1$  and  $\beta_2$  should not be interpreted separately and are therefore not reported. Fortunately, these high correlations do not affect the reliability of the joint effect of  $D$  and  $D/(t-R)^\mu$  within the study period (Verbeek, 2008, Chapter 2). The estimates of  $Ref_{inst}$ ,  $Ref_{mean}$ , and

$Ref_{end}$  as well as the predictions depicted in Figure 2 are thus still reliable and retain small confidence intervals despite these correlations.

The time trend estimate is positive in all populations and largest for *Others*. When the products' pre-reform sales values are used as weights, instead of the sales values for the entire study period,  $Ref_{mean}$  shrinks in absolute size for *Generics* and for *BrandM* to  $-6.86\%$  and  $-9.31$ , while it increases in absolute size to  $-15.89\%$  for *BrandM* and to  $-5.91$  for *Others*. In total, the weighted average reform effect is reduced in absolute size by half a percentage point.<sup>15</sup>



Note: The estimated reform effects illustrated here do not include the effect that the reform has by amplifying the effect of generic competition.

Figure 2. Estimated reform effects

<sup>15</sup>The weighted average reform effect is considerably larger when using a specification that allows the slope of the time trend to change at the time of the substitution reform. There is, however, reason to believe that this specification is inappropriate. Quite apart from the reasons mentioned previously in the text, the results obtained using this specification cast doubt on its validity. For example, the results for brands indicate that the reform effect is of the same size irrespective of whether or not the product faces generic competition.

## 4.2 Estimated demand and welfare effects

The first column of Table 4 presents the OLS results for specification (D1) (the first-difference), while the second and third columns present the OLS and IV results for specification (D2). No strong and valid instruments are found for  $\Delta \ln P$ , so the IV results for the first-difference specification are not reported.

Table 4. Estimation results for pharmaceutical demand, multiplied by 100

	Specification D1	Specification D2	
	OLS (first-diff.)	OLS	IV
$\ln P$	-75.83** (-130.51:-21.15)	-32.86* (-57.56:-8.16.)	-35.23* (-64.71:-5.75.)
$\ln I$	45.49* (8.75:82.24)	8.14 (-28.39:44.66)	10.11 (-23.23:43.45)
$Trend^{\mathfrak{N}}$	1.08* (0.18:1.98)	-0.10 (-0.55:0.35)	-0.14 (-0.61:0.34)
$Quarter_2$	4.01** (2.40:5.64)	3.11** (1.05:5.17)	3.04** (1.20:4.87)
$Quarter_3$	-7.36** (-11.50:-3.23)	-9.69** (-14.27:-5.11)	-9.46** (-13.81:-5.11)
$Quarter_4$	-2.60 (-5.47:0.27)	6.34** (2.20:10.47)	6.23** (2.85:9.61)
$Hoard$	-0.30** (-0.50:-0.10)	-0.52** (-0.84:-0.21)	-0.53** (-0.82:0.24)
$\ln Q_{t-1}$		59.99** (47.94:72.05)	60.23** (48.95:71.51)
$\ln Q_{t-4}$		35.09** (25.42:44.76)	35.48** (26.51:44.46)
Observations	111	108	108
AIC	-341.58	-365.48	-365.45
R <sup>2</sup>	0.8642	0.9955	0.9955
Kleibergen-Paap			30.32
Hansen J (P-value)			0.22

Notes: Robust 95% confidence intervals are shown in parentheses.

\*\* and \* denote significance at the 1% and 5% percent levels, respectively.

<sup>$\mathfrak{N}$</sup> Note that *Trend* only becomes a constant in the first-difference specification.

Let us start by noting that the estimates obtained using specification (D1) differ quite substantially from those obtained using specification (D2). This is expected, since the estimates of specification (D1) describe how changes in the independent variable affect the change in demand, while the estimates of specification (D2) – given the high coefficients for lagged consumption – more or less describe how the level of the independent variable affects the change in demand. As discussed above, the coefficients for lagged consumption can easily capture the effects of omitted variables and should therefore not be interpreted as estimates of persistence in pharmaceutical consumption.

The OLS and IV estimates for specification (D2) differ less from each other. If prices are endogenous, we would expect the OLS estimate in the second column to be larger than the IV estimate for  $\ln P$ . This is what we see, but the difference is quite small and not statistically significant. The difference might still indicate that there is an endogeneity problem, but the problem seems small in relation to the problem caused by including lagged consumption. Therefore, I view the results for specification (D1) as the most reliable ones, and will focus my discussion on these estimates.

The price elasticity estimate for specification (D1) is  $-0.76$  and significantly different from zero on the 1% level. It is more negative than most price elasticities for pharmaceuticals reported in the literature, but not directly comparable to many of those, since they measure the elasticities of pharmaceutical demand with respect to out-of-pocket prices for pharmaceuticals. If physicians' prescribing behavior is also affected by the costs to the insurers, this reduces the effect that changed copayments have on pharmaceutical demand.<sup>16</sup>

The price elasticity most comparable to the estimates reported here is perhaps that presented by Alexander et al. (1994). Using pharmaceutical consumption from seven countries over eight years, they estimated the price elasticity to be  $-3.25$ . I share the opinion of Alexander et al., who found it "very surprising" that the demand for pharmaceuticals was so elastic. If pharmaceutical products are substitutes for each other, the own-price elasticity of individual products should be below that of pharmaceuticals as a group.<sup>17</sup> This, in combination

---

<sup>16</sup>Gemmill et al. (2007) list elasticities from 22 papers investigating the effect of out-of-pocket prices for pharmaceuticals; these elasticities range from  $-0.80$  to  $-0.02$  and have a mean of  $-0.21$ .

<sup>17</sup>Some products are likely complements, but for the whole pharmaceutical market the complementarity is likely dominated by substitutability.

with pharmaceutical firms high mark-ups over marginal cost, suggests that a price elasticity of  $-3.25$  is not in accordance with the behavior of well-informed profit-maximizing pharmaceutical firms: such an elastic demand suggests that the firms could raise profits by reducing prices. For example, if the price elasticity of a firm's products is  $-3$ , a price cut of 1% would increase revenues by nearly 2%. If the marginal costs are constant, this would raise the variable costs by 3% and thus increase the firms profit if the variable costs are less than  $2/3$  of the revenues.<sup>18</sup>

The income elasticity estimate of 0.45 differs significantly from both zero and one, indicating that pharmaceutical consumption is a necessity in the short run. This can be compared with the long-term estimates summarized by Getzen (2000), indicating that healthcare on a national level is a luxury, and the income elasticity of pharmaceuticals of 1.55 reported by Alexander et al. (1994). One explanation of these differences is that pharmaceutical demand reacts slowly to changes in income.

The results for specification (D1) also indicate a considerable seasonal variation, and growth over time, in pharmaceutical demand. The estimate of  $-0.003$  for the variable *Hoard* suggests that a change in pharmaceutical insurance that increases consumer prices for pharmaceuticals by 10% is preceded by a temporary increase of 3% in the demand.

Based on the estimated reform effects we can calculate that, without the price-lowering effect of the substitution reform, Sweden's pharmaceutical consumption after the reform would have cost on average SEK 2.80 billion more per year in the study period. This is, however, not a very exact measure of the importance of the reform, since the pharmaceutical consumption would have been lower without the price-lowering effect of the reform.

A better measure is equivalent variation (EV). Using the price and income elasticities of specification (D1), the average annual EV measure in the study period is estimated to be SEK 2.68 billion, which can be compared with total Swedish pharmaceutical sales of SEK 26.43 billion in 2006. The increase in welfare is estimated to be SEK 1.80 billion in 2003 and SEK 3.30 billion in

---

<sup>18</sup>I obtained results similar to those of Alexander et al. by estimating a specification similar to theirs, but concluded that the results likely were spurious, since statistical tests suggested that the included time series were non-stationary and not cointegrated. The main difference compared with specification (D1) was that no first-difference transformation was done, and that the natural logarithm of the trend variable was used.

2006. Using a real discount rate of 3%, the present value in 2002 of the welfare effects for October 2002 through October 2007 amounts to SEK 12.42 billion.

Since the estimates reported in Table 4 are not very robust, I have also calculated the EV measures using other values for the price and income elasticities. Zero is a logical upper bound for the price elasticity and gives a present value of the welfare effects of SEK 12.96 billion. Economic theory provides no natural lower bound for the price elasticity; instead I report that the present value becomes SEK 12.05 billion when the price elasticity is set to  $-1.31$  (the lower limit of the 95% confidence interval of specification (D1)), and SEK 10.86 billion when it is set to  $-3.25$  (the estimate reported by Alexander et al.). The EV measures are only marginally affected by the income elasticity: if the income elasticity is set to 1.55 (the estimate reported by Alexander et al.), the present value remains at SEK 12.42 billion, and if it is set to 0 it becomes SEK 0.01 billion higher.

The welfare estimate reported above measures the value for the whole consumer-side of the market, both directly for the consumers and for the insurers. That the estimated price elasticity is above  $-1$  implies that the substitution reform has reduced pharmaceutical expenditures. The average reduction for October 2002 through October 2007 is 2.5% and the present value of the reduced expenditures amounts to SEK 3.00 billion. In this period, approximately 75% of the pharmaceutical expenditures were paid by the insurer (the National Corporation of Swedish Pharmacies). This means that the insurers' costs have decreased by approximately SEK 2.25 billion (75% of the SEK 3.00 billion, actually somewhat more than this due to the non-linear construction of Swedish pharmaceutical insurance), meaning that approximately SEK 10 billion of the discounted welfare improvement accrues directly to the consumers.

In view of increased costs due to the substitution reform, the Pharmaceutical Benefits Board allowed the National Corporation of Swedish Pharmacies to increase its annual margins by SEK 56 million in 2003, and by an additionally SEK 20 million in 2006 (the National Corporation of Swedish Pharmacies, 2003; the Pharmaceutical Benefits Board, 2005). If the estimated average reform effect is adjusted for these increases, the estimated average annual EV measure shrinks from SEK 2.68 billion to SEK 2.62 billion and the discounted welfare effect goes from SEK 12.42 billion to SEK 12.15 billion.

## 5 Other welfare effects

The substitution reform of course has other welfare effects besides those on the consumer-side in the form of reduced prices. Below, I briefly discuss other important welfare effects, though it is beyond the scope of this paper to provide estimates of these.

The substitution of cheaper versions for prescribed pharmaceuticals has not only led to increased price competition but also to direct savings. A rough estimate of these savings is SEK 0.6 billion per year.<sup>19</sup> There are, however, reasons not to consider the entire savings as constituting a welfare improvement for consumers. Granlund and Rudholm (2008) reported that 17% of the consumers in the county of Västerbotten refused substitution and paid extra to get the prescribed instead of the generic (or parallel-imported) pharmaceutical. This indicates that they viewed the substitutes as inferior to the prescribed drugs. If some consumers who agree to substitution share this view (but think the price difference is too great), the increase in consumer welfare due to the exchange is less than the consumers' monetary savings from it. Even though this view can stem from by lack of information, it might affect consumer welfare. The Medical Products Agency (2004) reports that some consumers feel generic substitutes are less effective than brand-name pharmaceuticals; generic substitution might therefore affect patient willingness to follow physician recommendations. Generic substitution might also increase the risk that some consumers confuse different drugs.

Since the reform has made consumers and physicians more familiar to generic pharmaceuticals, it might have affected physicians' prescribing pattern. Generic substitution might also have increased the costs for the Pharmaceutical Benefits Board, which must make more decisions regarding price changes, and for physicians, who might have to answer questions about generic substitution from their patients.<sup>20</sup>

The total producer surplus of the pharmaceutical firms has clearly been reduced by the reform: the revenues have declined and the costs have increased

---

<sup>19</sup>This estimate is obtained by extrapolating to the whole of Sweden from data for the county of Västerbotten for January 2003–October 2006; see Granlund (2008) for a description of this data. The National Corporation of Swedish Pharmacies et al. (2003) estimated these savings to be SEK 0.5 billion based on national data for the first six months after the reform.

<sup>20</sup>Andersson et al. (2006) investigated physicians' opinions on and experiences of the Swedish substitution reform.



due to higher quantities. Some generic producers have likely benefited from the reform due to increased market shares, while the profits of brand-name producers have been affected most negatively. Generic substitution also reduces the expected profits arising from new pharmaceuticals and thus the incentive to invest in research and development. Since the Swedish pharmaceutical market is small from a global perspective, this effect is also small, though it will nevertheless affect consumers around the world.

## 6 Discussion

In this paper, the Swedish substitution reform was estimated to have reduced the average price of pharmaceuticals during October 2002 through October 2007 by 10%. The reform effect was found to be significantly greater for brand-name than for generic products. The results also suggest that the reform amplified the effect of generic entry on brand-name prices by a factor of ten. This in turn has contributed to the reform effect being of similar size for brand-name products, irrespective of whether a product gained generic competition before or after the reform.

The results confirm the conclusion of Granlund and Rudholm (2007), that pharmaceutical firms gradually adjusted their prices after the reform. The estimated reform effects reported here, however, were significantly larger than those obtained by Granlund and Rudholm. One important explanation is that the observations here were weighted to obtain estimates of welfare effects due to increased price competition. This paper also differs from Granlund and Rudholm (2007) by, for example, studying the effects on all pharmaceutical products sold in Sweden, by using longer time series, and by studying the effect on the prices charged by the pharmaceutical firms, instead of those charged by the pharmacies.

The reform effects reported here are also considerably larger than those that Buzzelli et al. (2006) estimated for 16 OECD countries. This difference could be because the Swedish reform was more successful in reducing prices than were the reforms of the other 15 countries Buzzelli et al. studied. The difference could also be because I, unlike them, used a specification that allowed for gradual price adjustments after the reform.

The results of this paper support the theoretical predictions of Frank and

Salkever (1992) by indicating that the effect of generic competition changes significantly when consumers become more price sensitive, as they did with the Swedish substitution reform.

The estimations of the demand for pharmaceuticals were troubled by the non-stationarity of the key variables, so the results of these estimations should be interpreted with caution. Fortunately, the welfare estimates expressed in equivalent variation are not very sensitive with respect to price and income elasticities, so the present value of the welfare effects remains between SEK 12 and 13 billion for reasonable values of the elasticities. These welfare estimates measure how consumer welfare is affected by the price reductions, both directly and through reduced costs for pharmaceutical insurance. Another important welfare effect is the reduced profits for brand-name producers, which in turn reduces their incentives to invest in research and development.

To conclude, this paper has demonstrated that the substitution reform has reduced pharmaceutical prices considerably. Even though more research is needed into other consequences of the reform, the reform has likely been welfare improving from a Swedish perspective. The result may differ from a global perspective, since most brand-name producers are located outside Sweden and since consumers all over the world are affected by reduced incentives for pharmaceutical research and development.

## References

- Alexander, DL, JE Flynn and LA Linkins (1994) Estimates of the demand for ethical pharmaceutical drugs across countries and time, *Applied Economics* 26, 821–826.
- Andersson, K, T Jörgensen and A Carlsten (2006) Physicians' opinions and experiences of the Pharmaceutical Benefits Reform, *Scandinavian Journal of Public Health* 34, 654–659.
- Andersson, K, G Bergström, MG Petzold and A Carlsten (2007) Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals, *Health Policy* 81, 376–384.
- Buzzelli, C, A Kangasharju, I Linnosmaa, and H Valtonen (2006) Impact of Generic Substitution on Pharmaceutical Prices and Expenditures in OECD Countries, *Journal of Pharmaceutical Finance, Economics and Policy* 15, 41–62.
- Caves, RE, MD Whinston and MA Hurwitz (1991) Patent expiration, entry and competition in the U.S. pharmaceutical industry: An exploratory analysis, *Brookings Paper of Economic Activity, Microeconomics*, 1–66.
- Chaudhuri, S, PK Goldberg and P Jia (2006) Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India, *American Economic Review* 96, 1477–1514.
- Frank, RG and DS Salkever (1992) Pricing, patent loss and the market for pharmaceuticals, *Southern Economic Journal* 59, 165–179.
- Frank, RG and DS Salkever (1997) Generic entry and pricing of pharmaceuticals, *Journal of Economics and Management Strategy* 6, 75–90.
- Getzen, TE (2000) healthcare is an individual necessity and a national luxury: applying multilevel decision models to the analysis of healthcare expenditures, *Journal of Health Economics* 19, 259–270.
- Gemmill, MC, Costa-Font, J and A McGuire (2007) In search of a corrected prescription drug elasticity estimate: A meta-regression approach, *Health Economics* 16, 627–643.
- Grabowski, HG and JM Vernon (1992) Brand Loyalty, entry and price competition in pharmaceuticals after the 1984 drug act, *Journal of Law and Economics* 35, 331–350.

- Granlund, D (2008) Does physicians' compensation affect the probability of their vetoing generic substitution, *Umeå Economic Studies* 729, Umeå University.
- Granlund, D and N Rudholm (2007) Consumer information and pharmaceutical prices: Theory and evidence, *Umeå Economic Studies* 709 Umeå University.
- Granlund, D and N Rudholm (2008) Consumer loyalty in the Swedish pharmaceutical market, *Umeå Economic Studies* 742, Umeå University.
- Greene, WH (2003) *Econometric analysis*, fifth edition. Prentice Hall: New York.
- Hausman, J (1981) Exact Consumer's Surplus and Deadweight Loss, *American Economic Review* 71, 662–676.
- Lu, ZJ and WS Comanor (1998) Strategic pricing of new pharmaceuticals, *Review of Economics and Statistics* 80, 108–118.
- LFNFS 2003:1 Läkemedelsförmånsnämndens föreskrifter om ansökan och beslut hos Läkemedelsförmånsnämnden. [The Pharmaceutical Benefits Board's regulations about application and decisions at the Pharmaceutical Benefits Board] (in Swedish).
- Medical Products Agency (2004) Biverkningsrapporter i samband med utbyte av läkemedel [Reports of side-effects in connection with exchange of pharmaceuticals] Stockholm (in Swedish).
- National Corporation of Swedish Pharmacies (2003) Bokslutskommuniké 2002 [Annual report communiqué 2002] Stockholm (in Swedish).
- National Corporation of Swedish Pharmacies, The Federation of Swedish County Councils and the Pharmaceutical Benefits Board (2003) Utbyte av läkemedel – En uppföljning av de första sex månaderna med den nya reformen [Substitution of pharmaceuticals – The first 6 months with the new reform] Stockholm (in Swedish).
- National Corporation of Swedish Pharmacies, The Federation of Swedish County Councils and the Pharmaceutical Benefits Board (2004) Utbyte av läkemedel – En uppföljning av de första 15 månaderna med läkemedelsreformen [Substitution of pharmaceuticals – The first 15 months of the substitution reform] Stockholm (in Swedish).

- Pharmaceutical Benefits Board (2005) Höjd marginal för apoteket [Increased margins for the Pharmacy] Stockholm (in Swedish).
- Reekie, WD (1978) Price and quality competition in the United States drug industry, *Journal of Industrial Economics* 26, 223–237.
- RFFS 1992:20 Riksförsäkringsverkets föreskrifter om fastställande av pris på läkemedel [The National Social Insurance Board’s regulations for establishing prices for pharmaceuticals] (in Swedish).
- RFFS 1996:31 Riksförsäkringsverkets föreskrifter om fastställande av pris på läkemedel m.m. [The National Social Insurance Board’s regulations for establishing prices for pharmaceuticals etc.] (in Swedish).
- SFS 1981:49 Lag om begränsning av läkemedelskostnader, m.m. [Law (1981:49) concerning limitations of pharmaceutical costs, etc.] (in Swedish).
- SFS 2002:687 Förordning om läkemedelsförmåner m.m. [Ordinance (2002:687) on Pharmaceutical Benefits, etc.] (in Swedish).
- Watal, J (2000) Pharmaceutical patents, prices and welfare losses: Policy options for India under the WTO TRIPS agreement, *World Economy* 23, 5–21.
- Verbeek, M (2008) *Modern Econometrics*, third edition. John Wiley and Sons Ltd: West Sussex.
- Wiggins, SN and R Maness (1994) Price competition in pharmaceutical markets. Department of Economics, Texas A&M University. Unpublished manuscript.